{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:17:41Z","timestamp":1760955461713,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006366","name":"Minist\u00e9rio da Educa\u00e7\u00e3o","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jim.2013.10.011","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T05:34:15Z","timestamp":1383802455000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Reduction of cell viability induced by IFN-alpha generates impaired data on antiviral assay using Hep-2C cells"],"prefix":"10.1016","volume":"400-401","author":[{"given":"Edson R.A.","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna M.M.P.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlamir C.","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina M.","family":"de A. Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jim.2013.10.011_bb0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/08916930903510971","article-title":"Type I interferon therapy and its role in autoimmunity","volume":"43","author":"Biggioggero","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jim.2013.10.011_bb0010","first-page":"4948","article-title":"Comparative antiproliferativeactivity in vitro of natural interferons a and b for diploidand transformed human cell lines","volume":"42","author":"Borden","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2013.10.011_bb0015","series-title":"The European Pharmacopeia 6th ed., Strasbourg, France","first-page":"627","article-title":"Assay of Interferons","author":"Council of Europe","year":"2008"},{"issue":"3","key":"10.1016\/j.jim.2013.10.011_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.jim.2013.10.011_bb0025","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/ASO.2003.03.010","article-title":"Interferon-betais more potent than interferon-alpha in inhibition of human hepatocellularcell growth when used alone and in combination withanticancer drugs","volume":"10","author":"Damdinsuren","year":"2003","journal-title":"Ann. Surg. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.jim.2013.10.011_bb0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jim.2011.11.005","article-title":"Potency determination of recombinant IFN-alpha based on phosphorylated STAT1 using flow cytometry","volume":"375","author":"de Oliveira","year":"2012","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.jim.2013.10.011_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/gene.2008.87","article-title":"Human interferon-lambda3 is a potent member of the type III interferon family","volume":"10","author":"Dellgren","year":"2009","journal-title":"Gene. Immun."},{"key":"10.1016\/j.jim.2013.10.011_bb0040","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","article-title":"Interferon-a and cancer: mechanisms of action and new perspectives of clinical use","volume":"89","author":"Ferrantini","year":"2007","journal-title":"Biochimie"},{"key":"10.1016\/j.jim.2013.10.011_bb0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bjc.6605574","article-title":"NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation","volume":"102","author":"Hosono","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.jim.2013.10.011_bb0050","first-page":"613","article-title":"Type I interferon prolongs cell cycleprogression via p21WAF1\/CIP1 induction in human colon cancer cells","volume":"31","author":"Katayama","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.jim.2013.10.011_bb0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/jir.2012.0110","article-title":"Interferons as inducers of apoptosis in malignant cells","volume":"33","author":"Kotredes","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"issue":"7","key":"10.1016\/j.jim.2013.10.011_bb0060","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4161\/cbt.7.7.6192","article-title":"IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK\/STAT signaling activity","volume":"7","author":"Maher","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.jim.2013.10.011_bb0065","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cgh.2009.05.003","article-title":"Efficacy of chronic hepatitis C therapy in community-based trials","volume":"7","author":"Marotta","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jim.2013.10.011_bb0070","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/sj.onc.1201745","article-title":"Interferon-\u03b1-induced G1phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages","volume":"16","author":"Matsuoka","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.jim.2013.10.011_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-1759(01)00570-1","article-title":"Biological assays for interferons","volume":"261","author":"Meager","year":"2002","journal-title":"J. Immunol. Methods"},{"year":"2006","series-title":"The Interferons","author":"Meager","key":"10.1016\/j.jim.2013.10.011_bb0080"},{"key":"10.1016\/j.jim.2013.10.011_bb0085","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jpba.2008.11.010","article-title":"Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA","volume":"49","author":"Moore","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1\u20132","key":"10.1016\/j.jim.2013.10.011_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2013.10.011_bb0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/jhep.2001.21749","article-title":"Interferon-\u03b1 delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin dependent kinases","volume":"33","author":"Murphy","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jim.2013.10.011_bb0100","first-page":"52","article-title":"Effect of interferon on cell cycle phases in cultured human tumor cells","volume":"6","author":"Nikolaeva","year":"1984","journal-title":"Eksp. Onkol."},{"issue":"4","key":"10.1016\/j.jim.2013.10.011_bb0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2010.07.043","article-title":"Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy","volume":"54","author":"Oze","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jim.2013.10.011_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jir.1997.17.355","article-title":"Interferon-b induces S phase accumulation selectively in human transformed cells","volume":"17","author":"Qin","year":"1997","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jim.2013.10.011_bb0115","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.V65.4.858.858","article-title":"The effect ofrecombinant-DNA-derived interferons on the growth of myeloidprogenitor cells","volume":"65","author":"Rigby","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.jim.2013.10.011_bb0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jim.2013.10.011_bb0125","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1038\/sj.onc.1202609","article-title":"Molecular mechanisms underlying interferon-\u03b1-induced G0\/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins","volume":"18","author":"Sangfelt","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.jim.2013.10.011_bb0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.onc.1200832","article-title":"Induction of Cip\/Kip and Ink4 cyclin-dependent kinase inhibitors by interferon-\u03b1 in hematopoietic cell lines","volume":"17","author":"Sangfelt","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.jim.2013.10.011_bb0135","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.jim.2013.10.011_bb0140","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1091\/mbc.e06-09-0843","article-title":"A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis","volume":"18","author":"Scarzello","year":"2007","journal-title":"Mol. Biol. Cell"},{"issue":"5","key":"10.1016\/j.jim.2013.10.011_bb0145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/07357907.2011.568566","article-title":"Interferon-alpha induces G1 cell-cycle arrest in renal cell carcinoma cells via activation of Jak-Stat signaling","volume":"29","author":"Shang","year":"2011","journal-title":"Cancer Invest."},{"key":"10.1016\/j.jim.2013.10.011_bb0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.biologicals.2008.06.003","article-title":"Physicochemical and biological assays for quality control of biopharmaceuticals: Interferon-alfa 2 case study","volume":"36","author":"Silva","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2013.10.011_bb0155","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.onc.1201712","article-title":"Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line","volume":"16","author":"Subramaniam","year":"1998","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jim.2013.10.011_bb0160","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2010.01.016","article-title":"High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin","volume":"52","author":"Wirth","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jim.2013.10.011_bb0165","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/hep.510290624","article-title":"Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines","volume":"29","author":"Yano","year":"1999","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jim.2013.10.011_bb0170","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1440-1746.2006.04357.x","article-title":"Growth inhibitory effects of interferon-alpha subtypes vary according to human liver cancer cell lines","volume":"21","author":"Yano","year":"2006","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175913002913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175913002913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:34:30Z","timestamp":1758299670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175913002913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":34,"alternative-id":["S0022175913002913"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2013.10.011","relation":{},"ISSN":["0022-1759"],"issn-type":[{"type":"print","value":"0022-1759"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of cell viability induced by IFN-alpha generates impaired data on antiviral assay using Hep-2C cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2013.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}